Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01253681 | Study of AMG 386 in Combination With Paclitaxel and Carboplatin in Subjects With Ovarian Cancer | PHASE1 | COMPLETED | 27 | — | — | Nov 1, 2010 | Jan 1, 2015 | Oct 14, 2015 | 8 | Australia, Belgium +1 |
| Arm | Type | Description |
|---|---|---|
| AMG 386, paclitaxel and carboplatin | EXPERIMENTAL | 15 mg/Kg AMG 386 IV (intravenous) weekly plus paclitaxel and carboplatin IV Q3W for 18 weeks, followed by 15mg/Kg AMG 386 IV (intravenous) weekly alone for an additional 18 months. |
| Name | Type | Description |
|---|---|---|
| AMG 386, paclitaxel and carboplatin | DRUG | 15 mg/Kg AMG 386 IV (intravenous) weekly plus paclitaxel and carboplatin IV Q3W for 18 weeks, followed by 15mg/Kg AMG 386 IV (intravenous) weekly alone for an additional 18 months. |
Inclusion Criteria: * Female subjects more than 18 years of age with newly diagnosed high-risk FIGO Stage I (grade 3, or aneuploid grade 1 or 2) or Stages II-IV epithelial ovarian, primary peritoneal and fallopian tube cancer with an indication for first-line treatment with paclitaxel and carboplat...